Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00438984 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00438984: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
NCT00438984 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00438984, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may also stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate white blood cells to kill tumor cells. Giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin may be an effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects of giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin in treating patients with stage IV melanoma
Interventions
- DRUG cyclophosphamide
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium4 total trials
What the finished NCT00438984 record still lists
NCT00438984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00438984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00438984 about?
NCT00438984 is a clinical study titled "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma". RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT00438984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2006-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00438984?
The interventions under investigation include: cyclophosphamide (DRUG), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00438984?
This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00438984's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia